A systematic evaluation of structure-activity information led to the construction of genetically engineered interleukin 3 (IL-3) receptor agonists (synthokines) with enhanced hematopoietic potency. SC-55494, the most extensively characterized member of this series, exhibits 10-to 20-fold greater biological activity than recombinant human
Recombinant human interleukin (IL)-3 (rhIL-3) stimulates the proliferation and differentiation of hematopoietic progenitors in vitro and in vivo by triggering multipotent progenitor cell differentiation into the granulocyte, monocyte, erythroid, and megakaryocyte lineages (1, 2) . In addition, rhIL-3 primes cells to produce inflammatory mediators such as leukotriene C4 (LTC4) and directly triggers the synthesis and release of histamine (3, 4) .
The biological activities of rhIL-3 appear to be mediated by heterodimeric IL-3 receptors composed of two subunits, a unique 70-kDa a subunit and a common 130-kDa 13 subunit shared by the IL-3, IL-5, and granulocyte/macrophage-colonystimulating factor (GM-CSF) receptors (5) (6) (7) (8) . Although allelic isoforms of the a chain (9) have been reported, it appears that only one IL-3 receptor a-subunit gene and one (3-subunit gene are expressed in individual human cells. Despite the apparent identity of the IL-3 receptor 13 subunit on target cells, cytokine signaling pathways may be more complex than has been appreciated (10) . IL-3, IL-5, and GM-CSF stimulate unique biological responses, suggesting that the cellular distribution of effector molecules and the a subunit play specific roles. Further, the unique a chains of the IL-3, IL-5, and GM-CSF receptors have recently been shown to play a significant role in receptor signaling (11) (12) (13) .
Primate studies and clinical trials have shown that rhIL-3 can stimulate multiple hematopoietic lineages following myeloablation. Of particular interest is the ability of rhIL-3 to stimulate megakaryocyte expansion and platelet recovery (14) (15) (16) . Current
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clinical experience with rhIL-3 indicates that the therapeutic efficacy of this molecule may be limited by side effects such as fever, headache, neck rigidity, chills, rash, nausea, vomiting, and peripheral edema (17, 18) . At (22) to create an IL-3 a-receptor expression plasmid, pMON 3968, which was transfected into BHK cells (lacking endogenous a and a subunits) stably expressing the herpes simplex virus transactivator protein VP16 (22) . Forty-eight hours after transfection with pMON 3968 and pMON 1118 (expressing a hygromycin-resistance gene) (23) , the cells were split 1:25 and seeded into culture dishes with medium containing hygromycin (Calbiochem) at 453 units/ml. The colonies which had grown to confluence in 7 days were assayed for IL-3 a-receptor expression with an 125I synthokine as described below.
Receptor Ligands and Assay. Iodination of rhIL-3, which has only one tyrosine, yielded a low specific activity. To optimize iodination, a 14-aa N-terminal extension containing two tyrosine residues (Met-Ala-Tyr-Pro-Glu-Thr-Asp-TyrLys-Asp-Asp-Asp-Asp-Lys) was added to rhIL-3 to form a 147-aa receptor ligand. The same extension was added to a synthokine molecule with enhanced hematopoietic activity (synthokine 2, SC-65355) with seven amino acid changes from SC-55494 (Ala'9, Ala29, Val32, Leu42, Glu46, Ser47, Asn54), to form a 126-aa receptor ligand. The AML cell proliferation activity of synthokine 2 was 12-fold greater than rhIL-3. An SC-55494 (synthokine 1)-derived receptor ligand with the same extension was prepared and used in some studies with similar results (data not shown). Addition of the 14-aa extension to rhIL-3 decreased the biological activity (AML cell proliferation) by <30%, while addition of the extension to synthokines 1 and 2 increased biological activity (AML cell proliferation) by <30%. The ligands were 1251-labeled with Enzymobead reagent (Bio-Rad) to specific activities of 1-2 x 103 Ci/mmol as determined by ELISA or self-displacement analysis (24) . Both the 125I-synthokines and 125I-rhIL-3-derived ligand retained full biological activity in the AML 193.1.3 assay (data not shown).
Binding assays were performed at 4°C for 2-4 hr in 100 ,ul of IMDM containing 5% FBS, 50 ,tM 2-mercaptoethanol, 0.1% bovine serum albumin, and 0.2% sodium azide and terminated by centrifugation. Low-affinity (IL-3 a) receptor assays were carried out with 2-50 x 104 BHK cells stably transfected with IL-3 a-receptor cDNA (2-5 x 105 low-affinity sites per cell). High-affinity (a/(3) receptor assays were performed with 1-3 x 106 TF-1 or AML 193.1.3 cells expressing endogenous IL-3 receptor a and 13 subunits (500-1500 highaffinity sites per cell). Data were directly fit to bimolecular receptor-ligand equations by nonlinear regression (25) (26) (27) .
RESULTS
Biological Activity of Synthokine 1 (SC-55494). The molecular core required to maintain IL-3 activity was determined by sequential deletion of N-terminal and C-terminal amino acid residues. Over 4000 IL-3 receptor agonists were tested for biological activity to develop structure-activity relationships for the entire molecule. Point mutants were sequentially combined to generate molecules with increased hematopoietic activity relative to LTC4 priming and histamine release. SC-55494 has 48 amino acid sequence changes relative to rhIL-3, including the deletion of 13 N-terminal and 8 C-terminal residues, and 27 amino acid changes interspersed throughout the molecule (Fig. 1) .
The hematopoietic growth factor activity of SC-55494 was determined in the AML 193.1.3 cell proliferation and human marrow CFU assays. SC-55494 demonstrated significantly enhanced stimulation of the AML 193.1.3 cell line relative to rhIL-3 across the entire concentration range tested ( Fig. 2 ; Table 1 ). Twelve different preparations of SC-55494 were tested in at least three separate, triplicate assays. Comparison of the CFU response of human marrow CD34+ cells to SC-55494 and rhIL-3 demonstrated a 22-fold greater potency for SC-55494 ( Fig. 3; Table 1 ). In addition to a left shift in the dose-response curve, SC-55494 stimulated a greater frequency of colonies than rhIL-3 as illustrated by the higher plateau at high doses. Concentrations of rhIL-3 as high as 1 JIM did not stimulate a number of CFUs equal to that obtained with SC-55494 at 10 nM. Therefore, SC-55494 stimulated a greater number of myeloid progenitors than rhIL-3. In addition, SC-55494 treatment of human marrow resulted in larger granulocyte/monocyte (CFU-GM) colonies in the CFU assay relative to rhIL-3 at any given dose (data not shown). The In contrast to the 10-to 20-fold increased hematopoietic activity, cytokine-induced sulfidoleukotriene (LTC4) synthesis and release from peripheral blood cells was about 2-fold greater for SC-55494 than for rhIL-3 ( Fig. 4A ; Table 1 ). In histamine release assays using normal human peripheral blood leukocytes, SC-55494 was approximately twice as active as rhIL-3 (Fig. 4B) . Extensive in vivo studies in nonhuman primates have shown that SC-55494 does not possess greater inflammatory activity than rhIL-3 by physiological measures (data not shown). None of the inflammatory mediators measured (histamine, LTC4, tumor necrosis factor a, IL-6) were found to be increased in SC-55494-versus rhIL-3-treated animals (data not shown). The limited production of LTC4 was of key interest, since this response in human studies has been correlated with dose limitations for native rhIL-3 (18 (28) (Fig. 6 ; Table 2 ). In contrast, SC-55494 inhibited binding of 1251 synthokine to the a receptor with an ICso value of -3 nM, or about 60-fold lower than the value for rhIL-3 ( Fig. 6; Table 2 ). These IC50 values were confirmed with an independent a receptor-transfected BHK cell clone (data not shown). Similar IC50 values for SC-55494 and rhIL-3 were obtained by using the 125I-labeled rhIL-3-derived ligand (data not shown). Similar Ki values were found in competition experiments using five different lots of SC-55494, each assayed three times (see Table 2 ; P < 0.01).
Scatchard analysis of saturation data for 125I-SC-55494 binding to the a receptor gave a Kd value of 4.6 nM (Fig. 5) , which agreed well with the IC50 (Fig. 6) and Ki values ( tition experiments ( Table 2 ). The association rate of the synthokine ligand for the low-affinity (a) and high-affinity (a/03) receptors were similar. In contrast, the synthokine ligand's dissociation rate from the high-affinity (a/p3) receptor was significantly slower than its-dissociation rate from the low-affinity (a) receptor ('10-fold; P < 0.01). The SC-55494 association rate was significantly faster than the rhIL-3 ligand's association rate, with the high-affinity (a/a) receptor (-10-fold, P < 0.001). However, the high-affinity (a/a) dissociation rate constants for the synthokine and rhIL-3 ligands were not significantly different. A possible explanation for the synthokine's enhanced affinity for the high-affinity IL-3 a//3 receptor complex is its (-10-fold) faster association rate relative to rhIL-3, while the dissociation rates for SC-55494 and rhIL-3 are comparable. genitors may express different levels or ratios of the a and 13 receptor subunits compared with inflammatory mediatorreleasing cells in the periphery (e.g., eosinophils and basophils). Structural information derived from NMR methods indicates that a related IL-3 synthokine contains the characteristic four-helix topology seen in many cytokines plus a fifth, short helical segment (29) . An altered fifth helix in the synthokine may selectively change a/,B subunit pairing, resulting in differential activation of cellular proliferation versus inflammatory mediator release.
Alternatively, SC-55494 and IL-3 may induce differential coupling with kinases, such as Jak-2 (30), regulatory factors, such as phosphatases (31) , or signal transducers and activators of transcription, such as the recently described STAT (32) , to produce the observed selectivity. In the case of the hormone insulin, association of the effector with the hormone/receptor complex may account for a single receptor appearing to have different affinities in different tissues (33) . Similar intricacies may be involved in hematopoietic cytokine signaling.
Regions of the cytoplasmic domain of the human GM-CSF, IL-5, and IL-3 receptor a and 13 subunits appear essential for receptor function (11) (12) (13) 34) . Experiments using receptor chimeras indicate that dimerization of the human 13-subunit cytoplasmic domain can generate a proliferative signal when transfected into some murine cell lines but not others. In addition, GM-CSF and IL-3 a-subunit signaling in the absence of the 13 subunit has been reported (35, 36) . It is possible that the synthokine's 60-fold greater binding to the a subunit results in a selective signal for hematopoietic cell proliferation and differentiation. Continued research into the mechanism of IL-3 receptor signaling is likely to be the most productive approach to the understanding and further development of selective receptor agonists.
Hematopoietic growth factors have proven their efficacy in treating neutropenia associated with cancer therapy (37) . However, thrombocytopenia remains a significant clinical problem in myeloablated patients. The synthokine SC-55494 exhibits the intrinsic multilineage hematopoietic growth factor activity of rhIL-3 while enhancing its hematopoietic potency and potentially improving the therapeutic ratio of rhIL-3. Data from in vitro studies and from in vivo primate studies (38) suggest that administration of SC-55494 may stimulate marrow hematopoietic progenitor cells to replenish circulating neutrophils and platelets, thereby reversing the toxicity of many cancer therapy regimens.
